Bedaquiline Addendum

Bedaquiline (TMC207/BDQ) Addendum
Addendum to registration agreement for the NIH-AIDS Reagent Program (ARP)
Applicable to Bedaquiline (TMC207/BDQ)

Recipient agrees that bedaquiline (TMC207/BDQ), donated to the NIH-ARP, will only be used for in vitro studies of mycobacteria drug susceptibility testing, in vitro pharmacokinetic/pharmacodynamic studies including the Hollow Fiber System (HFS) and/or animal studies of mycobacterial infection models.

Category E: Non-profit Recipient must not use or incorporate the reagent for commercial purposes. Non-profit Recipient will seriously consider Janssen’s request for an exclusive, nonexclusive or partially exclusive royalty bearing license to make, use and/or sell products embodying inventions as claimed in any filed patent application, subject to the terms of 35 U.S.C. 207, 208, 209 and the implementing regulations.

Select all that apply for the intended use of Bedaquiline (TMC207/BDQ):

☐ In vitro studies of mycobacteria drug susceptibility testing
☐ In vitro pharmacokinetic/pharmacodynamics studies including the Hollow Fiber System (HFS)
☐ Animal studies of mycobacterial infection models
☐ Other – please briefly describe the research plan below:

Requesting Scientist: ____________________________
Signature: ________________________________
Title: ________________________________
Date: ____________________
Email Address: ________________________________